However, the preexisting and treatment-emergent ADA were not associated with any impact on clinical responses (day-28 response, duration of response, and event-free survival), cellular kinetics (maximum concentration and persistence), safety (CRS, neurologic events, or susceptibility to infection) or the initial expansion and persistence of tisagenlecleucel (31, 43). The gene discussed is ADA; the disease is congenital rubella syndrome.